Do analysts rate XBIO or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media refer more to XBIO or BTAI?

In the previous week, Xenetic Biosciences had 3 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 5 mentions for Xenetic Biosciences and 2 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.49 beat Xenetic Biosciences' score of 0.11 indicating that BioXcel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenetic Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BTAI or SKYE?

In the previous week, Skye Bioscience had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 6 mentions for Skye Bioscience and 2 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.49 beat Skye Bioscience's score of -0.55 indicating that BioXcel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Skye Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts prefer XCUR or BTAI?

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer XCUR or BTAI?

In the previous week, Exicure had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 3 mentions for Exicure and 2 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.49 beat Exicure's score of 0.17 indicating that BioXcel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALZN or BTAI?

In the previous week, BioXcel Therapeutics had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 2 mentions for BioXcel Therapeutics and 1 mentions for Alzamend Neuro. BioXcel Therapeutics' average media sentiment score of 0.49 beat Alzamend Neuro's score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alzamend Neuro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BioXcel Therapeutics (BTAI) Competitors

$0.07 +0.00 (+0.27%)

As of 09/4/2026

Compare

BTAI vs. XBIO, SKYE, XCUR, MTVA, and ALZN

Should you buy BioXcel Therapeutics stock or one of its competitors? BioXcel Therapeutics's main competitors and comparable companies include Xenetic Biosciences (XBIO), Skye Bioscience (SKYE), Exicure (XCUR), MetaVia (MTVA), and Alzamend Neuro (ALZN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioXcel Therapeutics compare to Xenetic Biosciences?

Xenetic Biosciences (NASDAQ:XBIO) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xenetic Biosciences has higher revenue and earnings than BioXcel Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.30	-$2.68M	-$1.16	N/A
BioXcel Therapeutics	$640K	3.63	-$69.90M	-$3.79	N/A

In the previous week, Xenetic Biosciences had 3 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 5 mentions for Xenetic Biosciences and 2 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.49 beat Xenetic Biosciences' score of 0.11 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenetic Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioXcel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xenetic Biosciences has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Xenetic Biosciences has a net margin of -75.90% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-75.90%	-40.62%	-34.97%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

Summary

Xenetic Biosciences and BioXcel Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Skye Bioscience?

BioXcel Therapeutics (NASDAQ:BTAI) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Skye Bioscience has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%
Skye Bioscience	N/A	-329.08%	-201.79%

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioXcel Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.9, meaning that its stock price is 190% more volatile than the broader market.

Skye Bioscience has lower revenue, but higher earnings than BioXcel Therapeutics. Skye Bioscience is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	3.63	-$69.90M	-$3.79	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$10.16	N/A

In the previous week, Skye Bioscience had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 6 mentions for Skye Bioscience and 2 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.49 beat Skye Bioscience's score of -0.55 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioXcel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Skye Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 14,744.80%. Skye Bioscience has a consensus target price of $64.00, suggesting a potential upside of 3,495.51%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe BioXcel Therapeutics is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

BioXcel Therapeutics beats Skye Bioscience on 9 of the 14 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Exicure?

Exicure (NASDAQ:XCUR) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Exicure has higher earnings, but lower revenue than BioXcel Therapeutics. Exicure is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	N/A	N/A	-$4.95M	-$1.32	N/A
BioXcel Therapeutics	$640K	3.63	-$69.90M	-$3.79	N/A

In the previous week, Exicure had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 3 mentions for Exicure and 2 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.49 beat Exicure's score of 0.17 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioXcel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exicure has a beta of 3.63, indicating that its share price is 263% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Exicure has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

42.8% of Exicure shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Exicure beats BioXcel Therapeutics on 8 of the 15 factors compared between the two stocks.

How does BioXcel Therapeutics compare to MetaVia?

BioXcel Therapeutics (NASDAQ:BTAI) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 14,744.80%. MetaVia has a consensus target price of $20.00, suggesting a potential upside of 1,097.60%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MetaVia has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%
MetaVia	N/A	-209.67%	-107.91%

BioXcel Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 0.6% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MetaVia has lower revenue, but higher earnings than BioXcel Therapeutics. MetaVia is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	3.63	-$69.90M	-$3.79	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

In the previous week, BioXcel Therapeutics had 2 more articles in the media than MetaVia. MarketBeat recorded 2 mentions for BioXcel Therapeutics and 0 mentions for MetaVia. BioXcel Therapeutics' average media sentiment score of 0.49 beat MetaVia's score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
MetaVia	Neutral

Summary

BioXcel Therapeutics beats MetaVia on 10 of the 15 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, BioXcel Therapeutics had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 2 mentions for BioXcel Therapeutics and 1 mentions for Alzamend Neuro. BioXcel Therapeutics' average media sentiment score of 0.49 beat Alzamend Neuro's score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alzamend Neuro	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioXcel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alzamend Neuro has higher earnings, but lower revenue than BioXcel Therapeutics. Alzamend Neuro is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.30	N/A
BioXcel Therapeutics	$640K	3.63	-$69.90M	-$3.79	N/A

49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 1,343.30%. BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Alzamend Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Alzamend Neuro has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-277.88%	-184.20%
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%

Alzamend Neuro has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

Summary

BioXcel Therapeutics beats Alzamend Neuro on 9 of the 15 factors compared between the two stocks.

Get BioXcel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTAI vs. The Competition

Export

Metric	BioXcel Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.32M	$3.92B	$7.26B	$13.23B
Dividend Yield	N/A	3.64%	2.53%	12.80%
P/E Ratio	-0.02	14.19	275.56	25.79
Price / Sales	3.63	1,580.83	693.67	102.99
Price / Cash	N/A	41.62	28.04	34.72
Price / Book	-0.02	15.60	10.56	6.36
Net Income	-$69.90M	-$22.86M	$3.49B	$358.17M
7 Day Performance	N/A	-1.24%	-0.23%	0.54%
1 Month Performance	N/A	-4.56%	-2.80%	-2.95%
1 Year Performance	N/A	38.32%	18.25%	6.08%

BioXcel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTAI BioXcel Therapeutics	2.1844 of 5 stars	$0.07 +0.3%	$11.00 +14,744.8%	-97.5%	$2.32M	$640K	N/A	90	Gap Up High Trading Volume
XBIO Xenetic Biosciences	1.066 of 5 stars	$3.98 -2.3%	N/A	-11.5%	$9.10M	$2.98M	N/A	4
SKYE Skye Bioscience	3.2242 of 5 stars	$2.05 -1.4%	$64.00 +3,022.0%	-94.5%	$9.08M	N/A	N/A	11	News Coverage Positive News
XCUR Exicure	0.9786 of 5 stars	$1.37 flat	N/A	-68.0%	$8.97M	$500K	N/A	50	Positive News Gap Up
MTVA MetaVia	2.0728 of 5 stars	$1.72 -2.0%	$20.00 +1,066.2%	-84.9%	$8.85M	N/A	N/A	8	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTAI) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. XBIO, SKYE, XCUR, MTVA, and ALZN

How does BioXcel Therapeutics compare to Xenetic Biosciences?

Summary

How does BioXcel Therapeutics compare to Skye Bioscience?

Summary

How does BioXcel Therapeutics compare to Exicure?

Summary

How does BioXcel Therapeutics compare to MetaVia?

Summary

How does BioXcel Therapeutics compare to Alzamend Neuro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. XBIO, SKYE, XCUR, MTVA, and ALZN

How does BioXcel Therapeutics compare to Xenetic Biosciences?

Do analysts rate XBIO or BTAI?

Do insiders & institutionals hold more shares of XBIO or BTAI?

Which has preferable valuation & earnings, XBIO or BTAI?

Does the media refer more to XBIO or BTAI?

Which has more volatility & risk, XBIO or BTAI?

Is XBIO or BTAI more profitable?

Summary

How does BioXcel Therapeutics compare to Skye Bioscience?

Is BTAI or SKYE more profitable?

Do insiders and institutionals have more ownership in BTAI or SKYE?

Which has more volatility and risk, BTAI or SKYE?

Which has higher valuation & earnings, BTAI or SKYE?

Does the media favor BTAI or SKYE?

Do analysts recommend BTAI or SKYE?

Summary

How does BioXcel Therapeutics compare to Exicure?

Do analysts prefer XCUR or BTAI?

Which has higher earnings & valuation, XCUR or BTAI?

Does the media prefer XCUR or BTAI?

Which has more risk and volatility, XCUR or BTAI?

Is XCUR or BTAI more profitable?

Do institutionals & insiders have more ownership in XCUR or BTAI?

Summary

How does BioXcel Therapeutics compare to MetaVia?

Do analysts prefer BTAI or MTVA?

Is BTAI or MTVA more profitable?

Which has more risk & volatility, BTAI or MTVA?

Do institutionals and insiders have more ownership in BTAI or MTVA?

Which has preferable valuation & earnings, BTAI or MTVA?

Does the media prefer BTAI or MTVA?

Summary

How does BioXcel Therapeutics compare to Alzamend Neuro?

Does the media prefer ALZN or BTAI?

Which has stronger earnings & valuation, ALZN or BTAI?

Do institutionals & insiders have more ownership in ALZN or BTAI?

Do analysts recommend ALZN or BTAI?

Is ALZN or BTAI more profitable?

Which has more volatility and risk, ALZN or BTAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools